MERS-CoV, SARS-CoV, SARS-CoV-2 Agent Information Sheet
Research Occupational Health Program (ROHP)
Coronaviruses are a large family of RNA viruses that are common in many different species of animals, including camels, cattle, cats, bats, and are cause of several epidemic and the recent SARS-CoV-2 pandemic. The name corona virus derives from the characteristic crown/spike appearance on electron micrographs. There are four major subtypes of coronaviruses relevant to humans: alpha, beta, gamma and delta. Human coronaviruses were first identified in the mid-1960s.
The seven coronaviruses that can infect people are:
Common human coronaviruses (worldwide incidence)
-229E (alpha coronavirus)
-NL63 (alpha coronavirus)
-OC43 (beta coronavirus)
-HKU1 (beta coronavirus)
Less common but highly pathogenic human coronaviruses:
-MERS-CoV (beta coronavirus causes Middle East Respiratory Syndrome, (MERS)
-SARS-CoV (beta coronavirus that causes severe acute respiratory syndrome, (SARS)
-SARS-CoV-2 (beta coronavirus that causes COVID-19)
Transmission occurs year-round in most parts of the world and novel coronaviruses can emerge from animal reservoirs and rapidly become epidemic.
Approximately 20% of COVID-19 infections result in severe illness; the case fatality rate is thought to be around 2% but data is evolving. The 2003 SARS outbreak had a case fatality rate of 9.6% The 2012 MERS outbreak had a case fatality rate was 34%. The spectrum of disease includes mild and asymptomatic infections that may not be detected resulting in an overestimate of case fatality rates.
Risk Group 3
Biosafety Level 3 practices
Modes of Transmission
|Skin Exposure (Needlestick, animal bite, or scratch):||Yes|
|Mucous Membrane Exposure Splash to Eye(s), Nose or Mouth:||Yes|
|Inhalation:||Transmission via droplets is the main route of exposure, for COVID19 airborne has not been ruled out|
|Ingestion:||Unlikely in laboratory setting|
Bats (SARS and SARS-COV-2), camels intermediate host (MERS), civets and humans.
For confirmed COVID-19 infections, reported illnesses have ranged from mild URI symptoms to severe illness and death from lower respiratory infection. Symptoms can include:
- Shortness of breath
2-14 days (possibly up to 20 days). Most case onset is 5 days following exposure.
Susceptible to: 62-71% ethanol, 0.5% hydrogen peroxide, 0.1% sodium hypochlorite, 5% MICRO-CHEM PLUS
Survival Outside Host
May persist on dry surfaces up to 24 hours or more. Under ideal temperature and humidity conditions, coronavirus in the research setting can persist up to 9 days.
Information for Lab Workers
Personal protective equipment includes but is not limited to laboratory coats or gowns, surgical masks, disposable gloves, safety glasses, face shield if risk of splash, and respirator (PAPR or N-95) if aerosol risk.
All work with infectious virus must be performed in BSL-3/ABSL-3 containment.
In Case of Exposure/Disease
- For injuries in the lab which are major medical emergencies (heart attacks, seizures, etc…):
- Medical Campus: call or have a coworker call the Control Center at 617-414–6666.
You will be referred to or transported to the appropriate health care location by the emergency response team.
- For lab exposures (needle sticks, bite, cut, scratch, splash, etc…) involving animals or infectious agents, or for unexplained symptoms or illness
to be connected with the BU Research Occupational Health Program (ROHP) medical officer. ROHP will refer you to the appropriate health care location.
- Under any of these scenarios, always inform the physician of your work in the laboratory and the agent(s) that you work with.
- Provide the wallet-size agent ID card to the physician.
None FDA approved vaccines for SARS, COVID19 or MERS.
Information for First Responders/Medical Personnel
Public Health Issues
After exposure: Immediately following an exposure to corona virus, the lab worker is not considered infectious. He/she can be cared for with standard PPE. In case of a lab worker presenting to Boston Medical Center Emergency Department or other outside medical facility, either the exposed worker or the caring physicians should immediately contact ROHP for further instructions.
In case of (suspected) illness: Lab worker should contact ROHP directly. The worker should be assessed for the severity of disease and dispositioned to the appropriate level of medical care or home quarantine as indicated based on consultation with the local public health department.
Person-to-person transmission is expected after symptoms occur and may be possible before the exposed worker is symptomatic based on the incubation period.
Viral detection is performed via Polymerase Chain Reaction (PCR).
Potential alternate diagnoses with similar presentation should be considered, such as influenza or other respiratory viruses.
Surveillance should be performed based on the current recommendations of the local public health department.
First Aid/Post Exposure Prophylaxis
Standard management of potential exposure to coronaviruses is solely based on observation, potential isolation and with symptomatic and supportive treatments.
No approved post exposure prophylaxis or post exposure vaccination is FDA approved.
Perform one of the following actions:
|Skin Exposure (Needlestick or scratch):||Immediately go to the sink and thoroughly wash the wound with soap and water for 15 minutes. Decontaminate any exposed skin surfaces with an antiseptic scrub solution.|
|Mucous Membrane Splash to Eye(s), Nose or Mouth:||Exposure should be irrigated vigorously.|
|Splash Affecting Garments:||Remove garments that may have become soiled or contaminated and place them in a double red plastic bag.|
Treatment is aggressive supportive care for severe illness and can be targeted towards symptom management for mild illness. There are no antivirals known to be effective.
Uptodate – Coronaviruses, https://www.uptodate.com/contents/coronaviruses
Uptodate – Coronavirus disease 2019 (COVID-19), https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19
Kampf, G, Todt, D, Pfaender, S, Steinmann, E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020 Feb 6 pii: S0195-6701(20)30046-3. Foi 10.1016/j.jhin.2020.01.22
CDC. (2020). Interim Laboratory Biosafety Guidelines: Covid-19. Retrieved from: https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html
DHHS, CDC & NIH. Biosafety in Microbiological and Biomedical Laboratories, 5th edn. (US Government Printing Office, Washington, DC, 2007). http://www.cdc.gov/OD/OHS/biosafety/bmbl5/bmbl5toc.htm p224-227.
Fields, B. N., Knipe, D. M., Howley, P. M., & Griffin, D. E. (2013). Coronaviruses Fields virology. Philadelphia: Lippincott Williams & Wilkins. Ch 28.